Overview
- In a 26-week ADJUST-T1D trial, adults with type 1 diabetes using automated insulin delivery achieved a 36% composite success rate on semaglutide versus 0% with placebo and saw an 8.8% increase in time spent in target glucose range.
- Participants receiving semaglutide lost an average of 8.8 kg more than those on placebo and lowered daily insulin doses by about 30%, with similar hypoglycemia rates and manageable gastrointestinal side effects.
- An analysis of 1.7 million type 2 diabetes records found semaglutide was linked to a significantly reduced risk of Alzheimer’s-related dementia compared to seven other antidiabetic medications, notably among women and older adults.
- Early clinical research combining semaglutide with the muscle-preserving antibody bimagrumab directed over 90% of average weight loss toward fat mass while safeguarding lean muscle.
- Investigators underscore that semaglutide’s emerging neuroprotective effects and type 1 diabetes benefits must be verified through larger randomized clinical trials to confirm causality and long-term safety.